


MEDraysintell publishes the 11th Edition of its Nuclear Medicine Report & Directory



MEDraysintell 11th Anniversary Edition of Nuclear Medicine Report

MEDraysintell releases the 11th Anniversary Edition of the Nuclear Medicine Report and Directory Edition 2024, comprising three volumes that provide a comprehensive and complete overview of the nuclear medicine landscape worldwide.

They include a detailed analysis of existing marketed products, an evaluation of all radiopharmaceuticals in clinical or early-stage development, and a description of all associated companies. In addition, the report provides a comprehensive review of the radiopharmaceuticals market, encompassing key market players, recent trends and growth opportunities.

This new Edition-2024 provides a comprehensive and exhaustive review of the radiopharmaceutical sector, encompassing **1,160 products**, including radionuclides, radiodiagnostic agents, and radiotherapeutics, along with in-depth profiles of more than **420 companies**. This information is presented across three volumes (Marketed, Clinical and Early-Stage Radiopharmaceuticals), spanning more than **4,030 pages**.

- MEDraysintell Nuclear Medicine (Part 1) Marketed Radiopharmaceuticals
- MEDraysintell Nuclear Medicine (Part 2) Clinical Radiopharmaceuticals
- MEDraysintell Nuclear Medicine (Part 3) Early-Stage Radiopharmaceuticals

Additionally, a database containing all the clinical and early-stage radiopharmaceuticals described in the reports can also be provided to assist users in their research.

To request a detailed table of contents and sample pages, please contact

Nicolas MARIO at <u>nicolas.mario@nucadvisor.com</u> or Vincent BRECHIN at <u>vincent.brechin@nucadvisor.com</u>

Numerous possibilities are present within the radiopharmaceutical sector. These opportunities extend beyond diagnostic radiopharmaceuticals. The pipelines for radiotherapeutic development reveal a substantial number of products that could potentially hit the market in the next few years. There are multiple openings for larger corporations or investors to fund these developments and potentially collaborate with strategic partners through M&A.

All of our press releases are available on: https://www.medraysintell.com/news-events

About MEDraysintell

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiopharmaceutical, cyclotron, proton therapy and brachytherapy.

MEDraysintell offers the most comprehensive set of reports and directories, with more than 5000 pages of unrivalled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client specific intelligence in the field of radiation healthcare, with the utmost knowledge leveraging our extended network of worldwide contacts.

We are proud to support numerous companies globally, helping them better understand the markets and competitive environment, the potential for mergers and acquisitions M&A) and technology development. We have repeatedly satisfied clients in the fields of medical radiation, investment banking and institutional investments, large international consulting firms, public institutions, and university research laboratories.

MEDraysintell (www.medraysintell.com) was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. In 2024, Nicolas Mario and Vincent Bréchin, who have respective nuclear engineering and medical science backgrounds, supported the integration of the MEDraysintell business into NucAdvisor (www.nucadvisor.com). The team also relies on an external network of specialists.

Contact

Vincent BRECHIN
Phone: +33 (0)1 40 88 41 43
Vincent.brechin@nucadvisor.com

Nicolas MARIO Phone: +33 (0)1 40 88 41 46

nicolas.mario@nucadvisor.com